James Mattern
Optometrist · Fairfax, VANPI 1104973205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Alcon at 25.8% of the total. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $38.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$2K
- Sight Sciences, Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$254
- NEW World Medical,inc.$217
- Dompe US, Inc.$203
- plus $1K from 15 others
What the payments were for
- Food & beverage$6,39698%
- Entertainment$1332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,682 |
| AbbVie(2 entities) | 61 | $1,521 |
| Sight Sciences, Inc. | 23 | $1,481 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $254 |
| NEW World Medical,inc. | 1 | $217 |
| Dompe US, Inc. | 4 | $203 |
| Sun Pharmaceutical Industries Inc. | 4 | $177 |
| Optos, Inc. | 2 | $133 |
| Bausch & Lomb Americas Inc. | 5 | $118 |
| Tarsus Pharmaceuticals, Inc. | 4 | $115 |
| Regeneron Healthcare Solutions, Inc. | 3 | $109 |
| Novartis | 4 | $94 |
| Aerie Pharmaceuticals, Inc. | 5 | $90 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| Biotissue Holdings Inc. | 3 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $52 |
| Glaukos Corporation | 1 | $47 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Rxsight Inc | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$830
- TEARCARE SYSTEM$381
- Clareon$243
- LUMIGAN$226
- PANORAMIC OPHTHALMOSCOPE$209
- OCT OPHTHALMOSCOPE$209
- Clareon PanOptix Pro$148
- ReSTOR$135
- AcrySof IQ PanOptix$131
- ACTIVEFOCUS$127
- Tecnis Multifocal Family of 1-piece IOLS$125
- Catalys Laser System$125
- Oxervate$122
- CEQUA$118
- Tecnis Toric 1-piece IOL$109
- NFC-700$105
How this compares
$6,530 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 178 | $100,300 |
| XiidraLifitegrast | 14 | $27,021 |
| RestasisCyclosporine | 14 | $23,451 |
| RhopressaNetarsudil Mesylate | 27 | $18,787 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $16,623 |
| Travoprost | 45 | $14,487 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $11,669 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 45 | $10,211 |
| VyzultaLatanoprostene Bunod | 21 | $8,958 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $4,943 |
| Alphagan PBrimonidine Tartrate | 11 | $4,620 |
| Prednisolone Acetate | 133 | $4,488 |
| Brimonidine Tartrate | 20 | $3,990 |
| Latanoprost | 232 | $2,446 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 129 | $2,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,521 | $144,994230 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $118 | $35,97935 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $90 | $30,45642 claims |
| AlconSimbrinza | $1,682 | $4,94314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Fairfax
- Walter WhitleyNorfolk$546K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
- Michael SwattsChesapeake$59K
- Kurt DevitoVirginia Beach$54K
- Walter SchlabachHarrisonburg$31K
- Mark AbrahamFalls Church$30K
- David TangVirginia Beach$29K
- Tiffany LioneAldie$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.